IL223871A - נגזרות קווינולין ומעכבי מלק המכילים אותן - Google Patents
נגזרות קווינולין ומעכבי מלק המכילים אותןInfo
- Publication number
- IL223871A IL223871A IL223871A IL22387112A IL223871A IL 223871 A IL223871 A IL 223871A IL 223871 A IL223871 A IL 223871A IL 22387112 A IL22387112 A IL 22387112A IL 223871 A IL223871 A IL 223871A
- Authority
- IL
- Israel
- Prior art keywords
- same
- quinoline derivatives
- inhibitors containing
- melk inhibitors
- melk
- Prior art date
Links
- 229940124787 MELK inhibitor Drugs 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36951910P | 2010-07-30 | 2010-07-30 | |
| PCT/US2011/045792 WO2012016082A1 (en) | 2010-07-30 | 2011-07-28 | Quinoline derivatives and melk inhibitors containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL223871A true IL223871A (he) | 2016-11-30 |
Family
ID=45530500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL223871A IL223871A (he) | 2010-07-30 | 2012-12-25 | נגזרות קווינולין ומעכבי מלק המכילים אותן |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9120749B2 (he) |
| EP (1) | EP2597955B1 (he) |
| JP (1) | JP5849303B2 (he) |
| KR (1) | KR101826382B1 (he) |
| CN (1) | CN103153063B (he) |
| AU (1) | AU2011282588B2 (he) |
| BR (1) | BR112013002182B8 (he) |
| CA (1) | CA2806332C (he) |
| DK (1) | DK2597955T3 (he) |
| ES (1) | ES2565627T3 (he) |
| IL (1) | IL223871A (he) |
| MX (1) | MX342879B (he) |
| RU (1) | RU2582610C2 (he) |
| SG (2) | SG187633A1 (he) |
| TW (1) | TWI532483B (he) |
| WO (1) | WO2012016082A1 (he) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2635279A4 (en) * | 2010-11-05 | 2014-10-29 | Glaxosmithkline Ip No 2 Ltd | CHEMICAL COMPOUNDS |
| CA2857346C (en) | 2012-01-19 | 2019-06-04 | Oncotherapy Science, Inc. | 1,5-naphthyridine derivatives and melk inhibitors containing the same |
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| US10254283B2 (en) | 2013-11-12 | 2019-04-09 | Dana-Farber Cancer Institute, Inc. | Biomarker for MELK activity and methods of using same |
| JP6535007B2 (ja) * | 2013-12-20 | 2019-06-26 | インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ | 新規ピペリジンカルボキサミド化合物、その調製方法及び使用 |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| US9862701B2 (en) | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| NZ732511A (en) * | 2014-12-15 | 2018-11-30 | Univ Michigan Regents | Small molecule inhibitors of egfr and pi3k |
| WO2016141296A1 (en) | 2015-03-04 | 2016-09-09 | Dana-Farber Caner Institute, Inc. | Tricyclic kinase inhibitors of melk and methods of use |
| EP3280708B1 (en) | 2015-04-10 | 2021-09-01 | Araxes Pharma LLC | Substituted quinazoline compounds and methods of use thereof |
| ES2856880T3 (es) | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos |
| CN108026046B (zh) * | 2015-07-22 | 2021-12-21 | 亚瑞克西斯制药公司 | 取代的喹唑啉化合物及其作为g12c突变体kras、hras和/或nras蛋白质的抑制剂的用途 |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| EP3325447A1 (en) * | 2015-07-22 | 2018-05-30 | Araxes Pharma LLC | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
| TW201718536A (zh) * | 2015-08-03 | 2017-06-01 | 必治妥美雅史谷比公司 | 可作為ＴＮＦα調節劑之雜環化合物 |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3364977A4 (en) | 2015-10-19 | 2019-09-04 | Araxes Pharma LLC | PROCESS FOR SCREENING INHIBITORS OF RAS |
| EA038635B9 (ru) | 2015-11-16 | 2021-10-26 | Араксис Фарма Ллк | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| RU2018126774A (ru) * | 2015-12-22 | 2020-01-23 | Витэ Фармасьютикалз, Инк. | Ингибиторы менин-mll взаимодействия |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| PT3484865T (pt) | 2016-07-14 | 2022-11-03 | Crinetics Pharmaceuticals Inc | Moduladores da somatostatina e suas utilizações |
| SG11201901435UA (en) | 2016-08-31 | 2019-03-28 | Oncotherapy Science Inc | Monoclonal antibody against melk and utilization thereof |
| US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| JP2019534260A (ja) | 2016-10-07 | 2019-11-28 | アラクセス ファーマ エルエルシー | Ｒａｓの阻害剤としての複素環式化合物およびその使用方法 |
| US10577365B2 (en) * | 2016-12-23 | 2020-03-03 | Felicitex Therapeutics, Inc. | Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| WO2018140600A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| MD3740475T2 (ro) | 2018-01-17 | 2022-09-30 | Crinetics Pharmaceuticals Inc | Procedeu de producere a modulatorilor somatostatinei |
| WO2019229765A1 (en) * | 2018-05-29 | 2019-12-05 | Council Of Scientific & Industrial Research, India | Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof |
| US12134620B2 (en) | 2018-08-01 | 2024-11-05 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
| CN109651355A (zh) * | 2019-01-24 | 2019-04-19 | 广西师范大学 | 3-(2-苯并五元杂环)-4-(3-二甲胺丙氨基)喹啉衍生物及其制备方法和应用 |
| CN109705037A (zh) * | 2019-01-24 | 2019-05-03 | 广西师范大学 | 4-氨基喹啉-3-甲酸酯衍生物及其制备方法和应用 |
| WO2020219729A1 (en) * | 2019-04-24 | 2020-10-29 | Children's Medical Center Corporation | Papd5 inhibitors and methods of use thereof |
| EP4167982A4 (en) * | 2020-06-22 | 2024-08-07 | PMV Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING FUNCTION OF P53 MUTANTS |
| WO2022015974A2 (en) * | 2020-07-15 | 2022-01-20 | St. Jude Children's Research Hospital, Inc. | Substituted 4-(3-aminoprop-1-yl)aminoquinoline analogs as modulators of melanoma-associated antigen 11 ubiquitin ligase |
| KR20230066379A (ko) | 2020-09-09 | 2023-05-15 | 크리네틱스 파마슈티칼스, 인크. | 소마토스타틴 조절제 제형 |
| WO2022087083A1 (en) * | 2020-10-21 | 2022-04-28 | Escient Pharmaceuticals, Inc. | Modulators of mas-related g-protein receptor x2 and related products and their use |
| KR20230155422A (ko) | 2020-12-22 | 2023-11-10 | 메카니스틱 테라퓨틱스 엘엘씨 | Egfr 및/또는 pi3k 억제제로서의 치환된 아미노벤질헤테로아릴 화합물 |
| WO2024220236A2 (en) * | 2023-04-21 | 2024-10-24 | University Of Georgia Research Foundation, Inc. | Hydroxylamine-based bcr-abl1 inhibitors for treatment of cancer |
| WO2025064853A1 (en) * | 2023-09-20 | 2025-03-27 | Momentum Therapeutics, Inc. | Ripk3 inhibitors and methods of use |
| WO2025147609A1 (en) * | 2024-01-05 | 2025-07-10 | Dewpoint Therapeutics, Inc. | Amino quinoline compounds and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1168801A (en) | 1966-05-13 | 1969-10-29 | May & Baker Ltd | Quinoline Derivatives |
| US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| TW200423938A (en) | 2003-02-21 | 2004-11-16 | Wyeth Corp | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
| BRPI0410720A (pt) | 2003-05-27 | 2006-06-20 | Pfizer Prod Inc | quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase |
| DE602005025231D1 (de) | 2004-08-10 | 2011-01-20 | Oncotherapy Science Inc | Gene und polypeptide in verbindung mit brustkrebserkrankungen |
| EP2011885B1 (en) | 2005-02-10 | 2015-04-22 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| WO2007013665A2 (en) | 2005-07-27 | 2007-02-01 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
| JP5249770B2 (ja) * | 2005-11-03 | 2013-07-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼインヒビターとして有用なアミノピリジン |
| ATE478849T1 (de) | 2006-04-14 | 2010-09-15 | Astrazeneca Ab | 4-anilinochinolin-3-carbonsäureamide als csf-1r- kinaseinhibitoren |
| WO2007139496A1 (en) | 2006-05-30 | 2007-12-06 | Clanotech Ab | Quinoline derivatives acting as tyrosine kinase inhibitors |
| WO2008023841A1 (en) | 2006-08-25 | 2008-02-28 | Oncotherapy Science, Inc. | Breast cancer-associated gene, melk, and its interactions with bcl-g |
| TW200829555A (en) * | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| PL2099796T3 (pl) | 2006-11-30 | 2011-10-31 | Genentech Inc | Związki azaindolilowe i sposoby ich zastosowania |
| CN100540551C (zh) * | 2007-02-01 | 2009-09-16 | 中国药科大学 | 喹啉衍生物、其制备方法及其医药用途 |
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| WO2009122180A1 (en) | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
| US20110212053A1 (en) | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
| CN102573846B (zh) * | 2009-08-17 | 2015-10-07 | 因特利凯公司 | 杂环化合物及其用途 |
| CA2857346C (en) * | 2012-01-19 | 2019-06-04 | Oncotherapy Science, Inc. | 1,5-naphthyridine derivatives and melk inhibitors containing the same |
-
2011
- 2011-07-28 MX MX2013001201A patent/MX342879B/es active IP Right Grant
- 2011-07-28 JP JP2013523213A patent/JP5849303B2/ja active Active
- 2011-07-28 BR BR112013002182A patent/BR112013002182B8/pt active IP Right Grant
- 2011-07-28 DK DK11813209.1T patent/DK2597955T3/en active
- 2011-07-28 CN CN201180047405.5A patent/CN103153063B/zh active Active
- 2011-07-28 WO PCT/US2011/045792 patent/WO2012016082A1/en not_active Ceased
- 2011-07-28 US US13/813,134 patent/US9120749B2/en active Active
- 2011-07-28 RU RU2013108865/04A patent/RU2582610C2/ru active
- 2011-07-28 SG SG2013006903A patent/SG187633A1/en unknown
- 2011-07-28 SG SG10201505951VA patent/SG10201505951VA/en unknown
- 2011-07-28 CA CA2806332A patent/CA2806332C/en active Active
- 2011-07-28 KR KR1020137005377A patent/KR101826382B1/ko active Active
- 2011-07-28 AU AU2011282588A patent/AU2011282588B2/en active Active
- 2011-07-28 EP EP11813209.1A patent/EP2597955B1/en active Active
- 2011-07-28 ES ES11813209.1T patent/ES2565627T3/es active Active
- 2011-07-29 TW TW100126942A patent/TWI532483B/zh active
-
2012
- 2012-12-25 IL IL223871A patent/IL223871A/he active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011282588A1 (en) | 2013-03-21 |
| CA2806332A1 (en) | 2012-02-02 |
| MX342879B (es) | 2016-10-14 |
| US9120749B2 (en) | 2015-09-01 |
| RU2013108865A (ru) | 2014-09-10 |
| EP2597955A1 (en) | 2013-06-05 |
| US20130217671A1 (en) | 2013-08-22 |
| JP2013532727A (ja) | 2013-08-19 |
| SG10201505951VA (en) | 2015-08-28 |
| KR101826382B1 (ko) | 2018-02-06 |
| BR112013002182B8 (pt) | 2023-02-28 |
| AU2011282588B2 (en) | 2016-01-07 |
| SG187633A1 (en) | 2013-03-28 |
| WO2012016082A1 (en) | 2012-02-02 |
| BR112013002182B1 (pt) | 2022-05-03 |
| CN103153063B (zh) | 2016-02-17 |
| CN103153063A (zh) | 2013-06-12 |
| DK2597955T3 (en) | 2016-03-14 |
| TW201208686A (en) | 2012-03-01 |
| EP2597955A4 (en) | 2014-02-19 |
| RU2582610C2 (ru) | 2016-04-27 |
| TWI532483B (zh) | 2016-05-11 |
| ES2565627T3 (es) | 2016-04-06 |
| JP5849303B2 (ja) | 2016-01-27 |
| BR112013002182A2 (pt) | 2016-05-31 |
| MX2013001201A (es) | 2013-04-03 |
| KR20130094312A (ko) | 2013-08-23 |
| HK1184331A1 (zh) | 2014-01-24 |
| EP2597955B1 (en) | 2016-01-20 |
| CA2806332C (en) | 2017-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL223871A (he) | נגזרות קווינולין ומעכבי מלק המכילים אותן | |
| ZA201301120B (en) | Heterocyclic compound and use thereof | |
| ZA201300374B (en) | Ampk-activating heterocyclic compound and methods for using the same | |
| IL252108A0 (he) | מעכבי cdk | |
| IL249669B (he) | 5–פלואורו–h1–פיראזולופירידינים מותמרים והשימוש בהם | |
| IL246600B (he) | תרכובות הטרוציקליות והשימוש בהן | |
| EP2637669A4 (en) | Heterocyclic compounds and their use | |
| ZA201305531B (en) | Selective glycosidase inhibitors and uses thereof | |
| IL220939A0 (en) | Compounds and methods | |
| EP2523664A4 (en) | COMPOUNDS AND METHODS | |
| IL222288A0 (en) | Heterocyclic compounds and their uses | |
| IL220812A0 (en) | Compounds and methods | |
| IL233529A0 (he) | נגזרות 1, 5–נפתירידין ומעכבי מלק המכילים אותן | |
| ZA201300036B (en) | Banzamide derivatives and their use as hsp90 inhibitors | |
| EP2523560A4 (en) | CONNECTIONS AND METHODS | |
| AP2012006419A0 (en) | Aminoquinoline derivatives | |
| PT2597084T (pt) | Derivado de n-hidroxiformamida e medicamento contendo o mesmo | |
| SI2655388T1 (sl) | Selektivni inhibitorji glikozidaze | |
| GB201018597D0 (en) | Inhibitors | |
| EP2626349A4 (en) | AMINE CONNECTION AND ITS USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |